- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01848054
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a prospective, randomized, multicenter, blinded, parallel-group, active-controlled, non-inferiority study conducted at 13 sites within the US. Eligible patients participated in 8 treatment visits on Days 1, 2, 3, 4, 8, 15, 22, and 29. Effectiveness of treatment was assessed as follows:
- Retention in treatment at Day 3
- Clinician and patient assessments of opioid withdrawal symptoms
- Assessment opioid cravings
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
-
Haleyville, Alabama, United States
-
-
California
-
National City, California, United States
-
Oceanside, California, United States
-
-
Florida
-
Jacksonville, Florida, United States
-
Maitland, Florida, United States
-
North Miami, Florida, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
-
Massachusetts
-
Fall River, Massachusetts, United States
-
-
Mississippi
-
Flowood, Mississippi, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read, comprehend, and sign the informed consent form and willingly provide written informed consent
- Prepared to engage in opioid replacement therapy and to abstain from opioid utilization other than the study drug, and from other illicit drugs
- Male or female, 18 to 65 years of age (inclusive)
- Met clinical criteria for opioid dependence in past 12 months based on DSM-IV-TR
- Provided buprenorphine-negative urine drug screen prior to randomization
- Provided negative urine pregnancy test
- Females of childbearing potential were required to be using a reliable method of contraception (e.g., hormonal, condom with spermicide, intrauterine device [IUD]) after the screening visit and for the duration of the study
- Participants receiving opioids for pain must receive clearance from their prescribing physician to be withdrawn from their prescribed opioids
- Generally good health as determined by the investigator
- Participants should demonstrate at least mild withdrawal symptoms (defined as a COWS score >9 at Day 1 predose)
Exclusion Criteria:
- Females who are pregnant or lactating, or planning to be pregnant during study
- Any previous prescribed treatment with buprenorphine monotherapy (e.g., generic buprenorphine sublingual tablets)
- Prescribed treatment with buprenorphine or naloxone within 90 days prior to start of treatment
- Methadone patients with any daily dose over 30 mg during the past week and who received the last dose of methadone less than 30 hours prior to start of treatment
- Participants who are unwilling or unable to comply with the requirements of the protocol
- Participants who are participating in any other clinical study in which medication(s) are being delivered or who have used an investigational drug or device within the last 30 days
- Participants with any known allergy or sensitivity or intolerance to buprenorphine, naloxone, or any related drug
- Participants who are on the staff, affiliated with, or a family member of the staff personnel directly involved with this study
- Participants with serious untreated Axis I DSM-IV-TR psychiatric comorbidity
- Tongue piercing or other piercings in the mouth, including lips and cheek
- Participants with current or history of clinically significant medical disorder or condition
- Participants who are human immunodeficiency virus (HIV)-seropositive with a CD4+ count <200 or active acquired immune deficiency syndrome (AIDS)
- Participants who have any Class III or IV congestive heart failure, symptomatic myocardial ischemia, a history of long QT syndrome.
- Participants who are currently taking Class 1A antiarrhythmic medications or Class III antiarrhythmic medications
- Participants who have uncontrolled hypertension or clinically significant ECG abnormalities
- Participants who have a pulse oximetry ≤93% at screening, due to any medical reason.
- Individuals with AST or ALT levels ≥3 X the upper limit of normal or total bilirubin or creatinine ≥1.5 X ULN, on the screening laboratory assessments
- Participants with known significant liver disease.
- Participants who take any medication, nutraceutical, herbal product with known CYP3A4 inhibition or induction properties within 14 days of screening.
- Participants who are at suicidal risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BNX Sublingual Tablets Induction
Day 1-2 (Blinded Induction): BNX sublingual tablets Day 3-28 (Open-label Maintenance): BNX sublingual tablets |
Advanced-formulation buprenorphine/naloxone sublingual tablets
Other Names:
|
ACTIVE_COMPARATOR: Buprenorphine Induction
Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets Day 3-28 (Open-label Maintenance): BNX sublingual tablets |
Buprenorphine sublingual tablets
Other Names:
Advanced-formulation buprenorphine/naloxone sublingual tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention in Treatment in the Per Protocol Population
Time Frame: Day 3
|
Retention in treatment at Day 3 in the per protocol population (n=256) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥-10% in the number of patients retained in treatment on Day 3.
|
Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC) in Clinical Opiate Withdrawal Scale (COWS) Total Score on Days 1 to 3 Inclusive
Time Frame: Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1
|
Least squares mean AUC in COWS total score on Days 1 to 3; COWS scores range from 0-48, with a lower score being more favorable
|
Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1
|
AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 3 Inclusive
Time Frame: Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1
|
Least squares mean AUC day 1 pre-dose through Day 3 in SOWS; SOWS scores range from 0-64, with a lower score being more favorable
|
Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1
|
AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 3 Inclusive
Time Frame: Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1
|
Least squares mean AUC measurement in VAS score for cravings on Days 1 to 3; the VAS craving scores range from 0 ("no cravings") to 100 ("most intense craving I have ever had")
|
Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1
|
Mean Change From Baseline in COWS Total Score After Day 3 (Maintenance Phase)
Time Frame: Predose on Days 4, 8, 15, 22, and 29
|
Mean change from baseline in COWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); COWS scores range from 0-48, with a lower score being more favorable
|
Predose on Days 4, 8, 15, 22, and 29
|
Mean Change From Baseline in SOWS Total Score After Day 3 (Maintenance Phase)
Time Frame: Pre-dose on Days 4, 8, 15, 22, and 29
|
Mean change from baseline in SOWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); SOWS scores range from 0-64, with a lower score being more favorable
|
Pre-dose on Days 4, 8, 15, 22, and 29
|
Mean Change From Baseline in the VAS Score for Cravings After Day 3 (Maintenance Phase)
Time Frame: Pre-dose on Days 4, 8, 15, 22, and 29
|
Mean change from baseline in VAS scores for cravings during the maintenance phase (Days 4, 8, 15, 22, and 29); the VAS craving scores range from 0 ("no cravings") to 100 ("most intense craving I have ever had")
|
Pre-dose on Days 4, 8, 15, 22, and 29
|
Retention in Treatment in the Full Analysis Population
Time Frame: Day 3
|
Retention in treatment at Day 3 in the full analysis population (N=310) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥-10% in the number of patients retained in treatment on Day 3.
|
Day 3
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lynn Webster, Life Tree Pain Clinic, 3838 S 700 E Suite 200, Salt Lake City, UT 84106
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Narcotic-Related Disorders
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
- Naloxone
- Buprenorphine, Naloxone Drug Combination
Other Study ID Numbers
- OX219-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-Related Disorders
-
Bicycle HealthEnrolling by invitationOpioid Use Disorder | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid MisuseUnited States
-
Baylor College of MedicineChandrakantanWithdrawnOpioid Dependence | Opioid Use | Opioid Abuse, Unspecified
-
University of ArkansasNational Institute on Drug Abuse (NIDA)CompletedOpioid Dependence | Opioid Withdrawal | Opioid DetoxificationUnited States
-
MindLight, LLCHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsCompletedOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of PennsylvaniaCompletedSurgery | Opioid Use | Opioid Misuse | Prescription Opioid MisuseUnited States
-
University of MinnesotaRecruitingOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
MindLight, LLCMclean HospitalRecruitingOpioid Dependence | Opioid Use | Opioid Abuse | Opiate Dependence | Opioid Use, Unspecified | Opioid Use Disorder, ModerateUnited States
Clinical Trials on Buprenorphine
-
Montefiore Medical CenterRecruiting
-
Steve N. Caritis, MDEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingPregnancy | Opiate AddictionUnited States
-
Indivior Inc.CompletedOpioid Use Disorder | Opioid-related DisordersUnited States
-
Indivior Inc.Completed
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)SuspendedExtended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use DisorderOpioid-use DisorderUnited States
-
Duke UniversityNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompletedOpioid Use DisorderUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedOpiate DependenceUnited States